Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro

David W. End,1 Gerda Smets, Alison V. Todd, Tanya L. Applegate, Caroline J. Fuery, Patrick Angibaud, Marc Venet, Gerard Sanz, Herve Poignet, Stacy Skrzat, Ann Devine, Walter Wouters, and Charles Bowden


ABSTRACT

R115777 [(B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone] is a potent and selective inhibitor of farnesyl protein transferase with significant antitumor effects in vivo subsequent to oral administration in mice. In vitro, using isolated human farnesyl protein transferase, R115777 competitively inhibited the farnesylation of lamin B and K-RasB peptide substrates, with IC50s of 0.86 nM and 7.9 nM, respectively. In a panel of 53 human tumor cell lines tested for growth inhibition, ~75% were found to be sensitive to R115777. The majority of sensitive cell lines had a wild-type ras gene. Tumor cell lines bearing H-ras or N-ras mutations were among the most sensitive of the cell lines tested, with responses observed at nanomolar concentrations of R115777. Tumor cell lines bearing mutant K-ras genes required higher concentrations for inhibition of cell growth, with 50% of the cell lines resistant to R115777 up to concentrations of 500 nM. Inhibition of H-Ras, N-Ras, and lamin B protein processing was observed at concentrations of R115777 that inhibited cell proliferation. However, inhibition of K-RasB protein-processing could not be detected. Oral administration b.i.d. of R115777 to nude mice bearing s.c. tumors at doses ranging from 6.25–100 mg/kg inhibited the growth of tumors bearing mutant H-ras, mutant K-ras, and wild-type ras genes. Histological evaluations revealed heterogeneity in tumor responses to R115777. In LoVo human colon tumors, treatment with R115777 produced a prominent antiangiogenic response. In CAPAN-2 human pancreatic tumors, an antiproliferative response predominated, whereas in C32 human melanoma, marked induction of apoptosis was observed. The heterogeneity of histological changes associated with antitumor effects suggested that R115777, and possibly farnesyl protein transferase inhibitors as a class, alter processes of transformation related to tumor-host interactions in addition to inhibiting tumor-cell proliferation.

INTRODUCTION

The Ras proteins have been the focus of oncology drug discovery efforts because of some unique features of the cellular metabolism of these proteins. To function in signal transduction and cell transformation, Ras must attach to the plasma membrane. This membrane localization is required for interactions with membrane receptors and the SH2/SH3 domain adaptor proteins Grb2 and SOS as well as for activation of a downstream effector(s), such as Raf protein kinase (1–4). Newly synthesized Ras proteins must be posttranslationally modified in mammalian cells by farnesylation and then by the proteolytic cleavage of the three terminal amino acids and carboxy-O-methylation to produce the hydrophobicity or recognition sites that allow proper membrane localization (5–7). The initial step catalyzed by FPT2 involves the covalent attachment of farnesol via a thioether linkage to a cysteine residue positioned four amino acids from the COOH-terminus of the protein (5, 8). The enzyme requires only the four COOH-terminal amino acids or CAAX motif for specific binding and catalysis of protein substrates.

The characteristic of FPT and tetrapeptide inhibitors of the enzyme set off a search for low-molecular weight, nonpeptide inhibitors that could be developed as therapy-selective for tumors bearing ras mutations (9). Initial studies with peptidomimetic compounds suggested that FTIs could, in fact, selectively inhibit the growth of ras-transformed cells (10–12). However, as experience with FTIs increased, the role of ras proteins in mediating the antitumor effects of this class of agent became less certain (13). As has been reported previously and in the current studies, FTIs have shown antiproliferative activity in tumor cell lines devoid of ras mutations (14). Also, the different H-Ras, N-Ras, and K-RasB isoforms were found to behave quite differently in the presence of FTIs. With isolated enzyme, the K-RasB protein demonstrated a higher affinity for FPT, which decreased the potency of FTIs competitive for the CAAX binding site (15). In intact tumor cells, the mutant, activated K-RasB and N-ras isoforms were associated with resistance to FTIs attributable to alternative processing by the parallel pathway of geranylgeranylation via GGPT I (16–18). However, as will be described, R115777 and other inhibitors have shown antiproliferative and antitumor activity in tumor cell lines bearing K-ras mutations (19, 20). At the moment, there is discordance between the antitumor activity of FTIs and the biology of Ras proteins. Several molecular targets such as RhoB and centromere-associated proteins (21–24) have emerged as possible downstream effectors for the FTIs. Treatment of cells with the FTI 1-739,749 induced an alternative processing of RhoB via PGGT I, with a gain of geranylgeranylated RhoB and concomitant reduction of the farnesylated RhoB (21). The accumulation of geranylgeranylated RhoB was associated with antiproliferative effects. Also in support of these observations, transfection of RhoB with CAAX motifs that restrict prenylation to geranylgeranylation reproduced many of the effects of FTI treatment, including reversal of the transformed phenotype as well as induction of apoptosis (23). However, recent studies have shown that expression of either farnesylated RhoB or geranylgeranylated RhoB produced similar tumor suppressive activity (25). Thus, the role of RhoB in the effects of FTIs is uncertain. Additionally, inhibition of the farnesylation of the centromere-associated proteins CENP-E and CENP-F has been linked to a G2-M growth arrest observed in some tumor cells in vitro (24). The current evidence suggests a role for multiple prenylated effectors in mediating the antitumor effects of FTIs. Involvement of multiple effectors might also be manifested as heterogeneous responses at the level of the tumor cell or intact tumors.

The current studies describe the preclinical pharmacology of R115777, a novel imidazole FTI that has entered Phase III clinical...
trials. Our findings will be discussed in relationship to the ras status of tumor cell lines as well as the heterogeneity of tissue responses observed in three human tumor xenografts after in vivo treatment with R115777.

MATERIALS AND METHODS

Compound. R115777 was synthesized as a racemate and purified as a single enantiomer by high-performance liquid chromatography.3 The structure is presented in Fig. 1.

Materials. Human tumor cell lines were purchased from the American Type Culture Collection (Rockville, MD). NIH 3T3 cells transfected with the activated T24 H-ras oncogene (T24 cells) or with activated Raf were obtained from Dr. Richard Connors, Janssen Research Foundation (Spring House, PA). The Farnesyl Protein Transferase Scintillation Proximity Assay, including the lamin B peptide substrate and the radiolabeled [1H]-farnesyl PP, was purchased from Amersham Life Sciences (Arlington, Heights, IL). The PGGT 1 peptide substrate biotin-YSNRSRCAIL was synthesized at Multiple Peptide Systems (San Diego, CA). [1H]-geranylgeranylpiphosphate was from DuPont NEN (Billerica, MA). The K-RasB peptide substrate biotin-KKKKKKSKTKCVIM was synthesized at the Robert Wood Johnson Pharmaceutical Research Institute Johnson and Johnson Biotechnology Center (La Jolla, CA). Antibodies to the Ras protein, v-H-Ras (Ab-1) conjugated to agarose, pan-Ras Ab-3, and RhoB were purchased from Oncogene Research Products (Cambridge, MA). Antibody to Rap 1A was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The secondary antibody antimouse IgG conjugated to horseradish peroxidase and the Enhanced Chemiluminescence reagents were purchased from Amersham Life Sciences. Precoat-20% SDS polyacrylamide slab gels were obtained from Integrated Separation Systems (Natick, MA). The primary antibodies used for immunocytochemistry included anti-BrdUrd clone BU-1 (Amersham, Buckinghamshire, United Kingdom), anti-Ki-67 clone MIB-1 (Novocastra, Newcastle upon Tyne, United Kingdom), anti-Factor VIII code A0082 (monoclonal; Dako, Glostrup, Denmark), and anti-VEGF A20 (Santa Cruz Biotechnology, Santa Cruz, CA).

Animals. Female nu/nu immunodeficient nude mice (42 days old) were purchased from Charles River Laboratories (Wilmington, MA). Mice were housed five per cage in microisolator cages placed in laminar flow shelving to maintain sterility. All bedding, food, water, and cages were autoclaved. Animals were handled within the sterile confines of a laminar flow cabinet. The mice were otherwise maintained under standard vivarium conditions. Tumor studies were conducted under a protocol approved by the Institutional Animal Care and Use Committee.

Isolation of DP and PGGT 1. FPT and PGGT 1 were isolated from Kirsten virus-transformed human osteosarcoma cell tumors essentially as described by Reiss et al. (8, 26). Tumors were excised and immediately homogenized in buffer (3.0 ml/tumor) containing 50 mM Tris, 1 mM EDTA, 1 mM EGTA, and 0.2 mM phenylmethylsulfonylfluoride (pH 7.5). The homogenate was centrifuged at 100,000 × g for 60 min, and a 30–50% ammonium sulfate precipitate was prepared from the supernatant. After dialysis, FPT and PGGT 1 activity were further isolated by ion exchange chromatography on Fast Q Sepharose. FPT was measured using the Amersham Scintillation Proximity Assay using the lamin B peptide substrate (Biotin-YSNRNRSCAIL) provided with the assay. In some studies, the K-RasB peptide (0.25 μM) was substituted for the lamin B peptide. PGGT 1 assays were performed using a modification of the Amersham Scintillation Proximity Assay methods. A biotin-YSNRNRSCAIL peptide substrate was incubated with [1-1H] [n]geranylgeranylpiphosphate for 120 min at 37°C. After termination reactions, samples were equilibrated overnight before counting.

Cell Proliferation Assays. Trypsinized cell suspensions were inoculated into six-well cluster dishes at an initial density of 200,000 cells/well in 3 ml of complete growth medium. R115777 was added at concentrations ranging from 0.5–500 nM in 3 μl of DMSO. Cells were allowed to proliferate to high saturation densities beyond confluence for 4–7 days. Cell numbers were quantified by detachment cell monolayers in 1 ml of trypsin and counting cell suspensions on a Coulter particle counter.

Analysis of Activating Mutations in ras Genes. DNA was prepared from human tumor cell monolayers using the DNAzol Reagent (Life Technologies, Inc.). An RFLP-PCR strategy was used to screen for activating mutations within K-ras, N-ras and H-ras (27). Exons 1 and 2 of all three ras genes were simultaneously amplified in a single multiplex reaction and an aliquot was used for a second round of PCR. Resistance to cleavage at natural or primer-induced restriction enzyme sites in second-round amplicons indicated the presence of a mutation that had abolished the site at the loci being analyzed. Restriction enzymes for the analysis of specific loci were BstNI (K-ras codon 12), BstI (K-ras codon 13, N-ras codons 12 and 13), MscI (H-ras codon 61; N-ras codon 61, positions 1 and 2), HaeIII (K-ras codon 61, position 1), Bfa I (N-ras codon 61, position 3), and Tru9I (K-ras codon 61, positions 2 and 3; H-ras intron D, position 2719). Reactions were digested overnight and PCR products were analyzed by gel electrophoresis. The correlation of ras mutation status versus sensitivity to R115777 were analyzed by a χ² test with sensitivity defined as 50% inhibition of cell proliferation at concentrations of ≤10 nm.

Analysis of Ras Protein Processing in Intact Cells in Culture. T24F1 or CAPAN-2 cells were grown as monolayers in T75 tissue culture flasks in 25 ml of complete growth medium. The monolayer cultures were treated with R115777 for 72 h. Then the growth medium was removed and the monolayers were washed once with 5 ml of PBS. Cells were harvested by scraping into ice-cold PBS and collected by centrifugation (1000 × g for 5 min). Total cellular Ras processing was analyzed in partuculate and soluble fractions of cells as described by Yan et al. (28). Detection of K-Ras immunoreactivity required immunoprecipitation with v-H-Ras antibody conjugated to agarose before electrophoresis and immunoblotting procedures. Protein determinations were performed on 5- to 10-μl samples of pellets and supernatants (29). Samples were normalized such that equal amounts of protein were added to Laemmli sample buffer and separated on 10–20% gradient SDS polyacrylamide slab gels. After transfer to polyvinylidene difluoride membranes, samples were incubated overnight at 4°C with primary antibodies. The immunostained antigens were visualized using horseradish peroxidase-conjugated secondary antibodies and Amersham enhanced chemiluminescence detection reagents.

Tumor Studies in Nude Mice. Tumor cell lines maintained as monolayer cultures were detached by trypsinization. Tumor cell suspensions were pooled and trypsin was inactivated by the addition of serum-containing medium. Cells were collected by centrifugation and washed once in HBSS. Cell suspensions were adjusted to a final concentration of 1 × 10⁶ cells/ml of HBSS. Mice were inoculated with a single s.c. injection of 0.10 ml of tumor cell suspension in the inguinal region of the thigh. Mice were housed five per cage, with 15 mice randomly assigned to treatment groups. Three days after tumor inoculation, treatment with R115777 was initiated. R115777 was administered b.i.d. by oral gavage in a 20% cyclodextrin vehicle as a volume of 0.10 ml of solution/10 g body weight. Control groups received the same dosage/volume of the 20% β-cyclodextrin vehicle. Body weight and tumor size as determined by caliper measurements were monitored weekly. At the end of study, mice were sacrificed by CO₂ asphyxiation. Tumors were excised, weighed, and fixed immediately in 4% paraformaldehyde. ANOVA, mean values for treatment groups, and SE for in vivo parameters were calculated using IMSL subroutines compiled by R. W. Johnson of the Pharmaceutical Research Institute, Science Information Department, on a VAX computer. A value of P < 0.05 was considered significant.

1 D. W. End, M. G. Venet, P. R. Angiband, and G. C. Sanz, the synthesis will be published elsewhere and can be found in patent WO 9716443 A1.

![Fig. 1. Structure of R115777.](132)
Preparation of Tumors for Histology. Fixed tumors were cut into thin fragments (approximately 10 x 10 x 3 mm). The tissues were rinsed overnight in 0.1 M phosphate buffer (pH 7.4). After dehydration in acetone, LoVo and CAPAN-2 tumors were infiltrated and embedded in Technovit 8100 (Kulzer, Wehrheim, Germany). C32 melanoma tumors were dehydrated in ethanol/xylol and infiltrated in paraffin block. For Technovit embedding, infiltration and embedding were performed under a nitrogen atmosphere at 0°C. Sections (3 μm) were cut with a Leica Jung Autocut and mounted onto glass slides by drying at 50°C for 2 days. Paraffin sections were mounted with Biobound-coating (British Biocell International, Cardiff, United Kingdom). After staining with erythrosine B and hematoxylin, the slides were mounted with Pertex (LED Techno, Hechtel, Belgium).

Immunocytochemistry. Sections were treated with a 1:10 dilution of Target Unmasking Fluid (Sanbio, Uden, the Netherlands) by heating to 90°C in a microwave oven. Slides were incubated with 0.5% trypsin solutions for 30 min at 37°C. The slides were extensively rinsed, and then endogenous peroxidase was blocked by incubating with 1% peroxyde in methanol for 15 min. Non-specific antibody-binding sites were blocked by incubation with 0.5% lysesom for 60 min. Incubations with the primary antibody were performed at room temperature at various times optimized for each antibody. Staining with the primary antibody was visualized using the biotin-avidin peroxidase method (Dako, Glostrup, Denmark) using Sigma Fast DAB (Sigma, St. Louis, MO). At the end of the procedure, the slides were counterstained with 0.25% methyl green. To monitor apoptosis, ISEL was performed according to the directions of the TACSTM1 Klenow Kit (Treiven, Gaithersburg, MD).

Quantitative image analysis was performed using a Zeiss Axioplan microscope fitted with CCD cameras interfaced to a Silicon Graphics Indy RS500 Unix-based workstation. Image analysis routines were written in C under the SCIL-Image software package (SCIL Image, Version 1.3; TNO-TPD, Delft, the Netherlands). For evaluation of BrdUrd-labeling and apoptosis, images were taken with a black and white CCD camera (MX5, Adimec, the Netherlands). For quantification of cell proliferation, the total number of cells was obtained by imaging the methyl green staining through a 650-nm broadband interference filter. To obtain images of the nuclei labeled with BrdUrd, the same microscopic fields were viewed with a 450-nm broadband interference filter. For quantifying Factor VIII and VEGF-staining, 24-bit RGB color images were acquired with a cooled CCD-camera (Sony DXC-930 P) and transformed to HSI-space. The immunocytochemical signal was quantified as a percentage of the area in a field. For measurements of BrdUrd incorporation and apoptosis, a ×20 objective was used; whereas, for VEGF- and Factor VIII-staining, a ×40 objective was used. The total areas on each slide evaluated for BrdUrd incorporation and Ki-67 staining was 4 mm². Apoptosis was evaluated in an 8-mm² area. The total number of cells quantified ranged from 8,000–25,000 cells/slide. Areas evaluated for Factor VIII- and VEGF-staining varied from 1–8 mm². Five tumors were evaluated from each treatment group.

Data from quantitative image analysis were analyzed by the Wilcoxon Mann-Whitney test. For proliferation and apoptosis, data were expressed as the percentage of positive cells-section and calculated as the mean ± SD for each tumor. For Factor VIII and VEGF staining, data were expressed as the percent area with staining signal versus the total section area viewed. These data were calculated as medians ± SE for each tumor.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>IC₅₀ (μM with 95% confidence limits) or % inhibition at highest tested concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isolated FPT</td>
<td>0.86 (0.61–1.2)</td>
</tr>
<tr>
<td>Lamin B CVIM peptide</td>
<td>7.9 (6.8–2.37)</td>
</tr>
<tr>
<td>K-RasB CVIM peptide</td>
<td></td>
</tr>
<tr>
<td>Isolated GGPT I</td>
<td></td>
</tr>
<tr>
<td>Lamin B CVIL peptide</td>
<td></td>
</tr>
<tr>
<td>Substrate-dependent growth of transfected NIH 3T3 fibroblasts</td>
<td>1.7 (1.3–2.4)</td>
</tr>
<tr>
<td>Untransfected</td>
<td>0% at 500 nM</td>
</tr>
<tr>
<td>T24 H-ras</td>
<td>0.5 at 10 nM</td>
</tr>
<tr>
<td>v-ras</td>
<td>0.5 at 10 nM</td>
</tr>
</tbody>
</table>

RESULTS

In Vitro Activity. R115777 inhibited isolated human FPT with IC₅₀ of 0.86 nM and 7.9 nM observed for a lamin B peptide and for the K-RasB peptide, respectively (Table 1). Consistent with this difference in potency for the two peptide substrates, kinetic studies revealed that R115777 was a competitive inhibitor for both the K-ras and lamin B1 peptide substrates (Kᵢ = 0.5 nm) and noncompetitive for the farnesylpyrophosphate substrate (data not shown). PGGT I activity was virtually insensitive to R115777, with only 40% inhibition of enzyme activity observed at 50 μM R115777.

R115777 penetrated cells quite readily, as evidenced by the activity of the compound in intact cells at nanomolar concentrations. The proliferation of T24 H-ras-transformed NIH3T3 cells was inhibited by R115777, with an IC₅₀ of 1.7 nM, whereas parental NIH 3T3 cells were unaffected by up to 500 nM R115777. The proliferation of NIH 3T3 cells transfected with an activated v-ras oncogene was also inhibited, but at higher concentrations (IC₅₀ = 97 nM). As has been reported previously for other FTIs, the inhibition of T24 H-ras-transformed NIH 3T3 cell proliferation by R115777 was accompanied by a morphological reversion of the H-ras-transformed phenotype to a quiescent, contact-inhibited phenotype with effects observed from 0.5–50 nM (data not shown; 10, 11).

The farnesylation of Ras protein was studied in T24 H-ras-transformed NIH3T3 cells by Western blot analysis with a pan-Ras antibody. Cells treated with 0.5–50 nM R115777 displayed a concentration-dependent accumulation of Ras immunoreactivity in the cytosol with a concomitant reduction of processed, particulate Ras immunoreactivity (Fig. 2). Visually obvious responses were obtained within the concentration ranges that inhibited cellular proliferation. However, antiproliferative and morphological effects were observed at R115777 concentrations lower than the 10-nM concentration that was required to deplete prenylated Ras. Therefore, depletion of fully processed, activated Ras protein was not required for the cellular effects of R115777.

Summarized in Table 2 are the results from examining the substrate-dependent proliferation of 53 human tumor cell lines. DNA prepared from each of the cell lines was analyzed for the presence of mutations in N-ras and K-ras at codons 12, 13, and 61 and in H-ras at codons 12 or 61 and position 2719 of intron D. Overall, 75% of the cell lines were sensitive to the antiproliferative effects of R115777 irrespective of ras gene mutations. Sensitivity was operationally defined as a 50% reduction in cell counts at concentrations of ≤100 nM.

Table 2. In vitro evaluation of R115777 with isolated enzymes and intact cells

<table>
<thead>
<tr>
<th>Parameter</th>
<th>IC₅₀ (μM with 95% confidence limits) or % inhibition at highest tested concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isolated FPT</td>
<td>0.86 (0.61–1.2)</td>
</tr>
<tr>
<td>Lamin B CVIM peptide</td>
<td>7.9 (6.8–2.37)</td>
</tr>
<tr>
<td>K-RasB CVIM peptide</td>
<td></td>
</tr>
<tr>
<td>Isolated GGPT I</td>
<td></td>
</tr>
<tr>
<td>Lamin B CVIL peptide</td>
<td></td>
</tr>
<tr>
<td>Substrate-dependent growth of transfected NIH 3T3 fibroblasts</td>
<td>1.7 (1.3–2.4)</td>
</tr>
<tr>
<td>Untransfected</td>
<td>0% at 500 nM</td>
</tr>
<tr>
<td>T24 H-ras</td>
<td>0.5 at 10 nM</td>
</tr>
<tr>
<td>v-ras</td>
<td>0.5 at 10 nM</td>
</tr>
</tbody>
</table>

The complete set of data can be obtained from the National Auxiliary Publications Service, c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513. Phone: (516) 481-2300; Fax:(516) 481-6213.
sensitive to R115777, with IC50 s for inhibition of proliferation ranging from 1–100 nM. Approximately 80% of the cell lines with wild-type ras were sensitive to R115777, with cells bearing wild-type ras mutants compared with ras wild type: sensitivity correlates with ras mutation status.

<table>
<thead>
<tr>
<th>Table 2 Summary of antiproliferative effects of R115777 in 53 human tumor cell lines grouped by ras gene status</th>
</tr>
</thead>
<tbody>
<tr>
<td>ras gene status</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Ras mutation</td>
</tr>
<tr>
<td>(any ras gene)</td>
</tr>
<tr>
<td>ras wild type</td>
</tr>
<tr>
<td>N-ras or H-ras mutation</td>
</tr>
<tr>
<td>K-ras mutation</td>
</tr>
</tbody>
</table>

* N-ras plus H-ras mutants compared with ras wild type: sensitivity does not correlate with ras mutation by χ² test.
* K-ras mutants compared with ras wild type: sensitivity correlates with ras mutation status.

Cell lines bearing H-ras or N-ras mutations were among the most sensitive to R115777, with IC50s for inhibition of proliferation < 10 nM. No evidence for resistance to R115777 was observed in N-ras mutated cell lines, as has been suggested previously (18). However, 50% of the cell lines bearing K-ras mutations were resistant to R115777. Cell lines bearing K-ras mutations that did respond to R115777 required higher concentrations, with IC50s ranging from 1–100 nM. Approximately 80% of the cell lines with wild-type ras were sensitive to R115777, which was consistent with previous data (14). Some clustering of sensitivity to R115777 was observed for tumor cell lines from similar tissue origins. For example, human bladder tumor, rhabdomyosarcoma, and melanoma cell lines were among the most sensitive to R115777, with cells bearing wild-type ras or ras mutations virtually indistinguishable in their responses (Table 3). Data for lung and pancreatic tumor cell lines are also summarized in Table 3 to exemplify the resistance observed in cell lines bearing K-ras mutations. In contrast to previous publications, A549 cells were relatively insensitive to R115777 (24, 30). This may reflect differences in experimental parameters as the former studies were conducted under conditions of anchorage-independent growth, which is an important consideration when assessing FTIs (31). Overall, the sensitivity of tumor cell lines to the FTI R115777 were consistent with data reported for cell line sensitivity to the FTI SACD-744,832 (14).

The CAPAN-2 cell line was selected as a human tumor cell line bearing a K-ras (12) mutation for additional examination of total cellular protein prenylation. Western immunoblot analysis using antibodies to lamin B and a pan-Ras antibody revealed a concentration-dependent accumulation of immunoreactivity in the soluble fraction from 1–100 nM R115777, which was interpreted as an accumulation of unfarnesylated protein (Fig. 3A). The majority of the pan-Ras immunoreactivity shifted to the cytosol was cross-reactive with an N-ras antibody (Fig. 3B). No H-Ras immunoreactivity was detected in CAPAN-2 particulate or soluble fractions. Immunoprecipitation before Western blot analysis was required to detect the low levels of K-Ras immunoreactivity in particulate fractions of CAPAN-2 cells. Although an increase in K-Ras immunostaining was noted after treatment with R115777, no increase in soluble K-Ras immunoreactivity (Fig. 3C) was noted. R115777 did not alter the distribution of Rap1a immunoreactivity, a geranylgeranylated protein, or RhoB immunoreactivity, a protein that can be farnesylated or geranylgeranylated (Fig. 3A). The results were consistent with the selectivity of R115777 observed in studies with isolated enzyme.

### In Vivo Activity

Data from in vivo tumor studies with R115777 are summarized in Table 4. A b.i.d. dosing schedule for R115777 was determined from plasma pharmacokinetics in mice (data not shown). Oral administration of R115777 at doses of 6.25, 12.5, and 25 mg/kg

![Antitumor Effects of Selective FTI R115777](image-url)
same letter are not statistically significant (aK -
inhibited the proliferation of LoVo human colon tumor cells bearing
shown). Significant changes in body weight were not observed for
the effects of R115777 on postmortem tumor weights (data not
studies, the weekly measurements of tumor area were consistent with
melanoma with an IC50 of 6 nM (Table 3). Oral administration of
in vivo
melanoma was selected as a representative wild-type
mined from postmortem tumor weights after 32 days of treatment.
antly inhibit tumor growth by 68% and 81%, respectively, as deter-
tumors during the 14 days of administration. Tumor growth measured
(b.i.d.) to nude mice bearing T24 tumors suppressed the growth of
tumors during the 14 days of administration. Tumor growth measured
as postmortem tumor weight was inhibited by 56%, 84%, and 86% at
the three respective dose levels. Consistent with the in vitro cell
proliferation data, higher doses of R115777 were required to inhibit
the growth of tumors bearing K-ras mutations. In vitro, R115777
inhibited the proliferation of LoVo human colon tumor cells bearing a
K-ras mutation with an IC50 of 16 nM. In nude mice bearing LoVo
tumors, doses of 50 and 100 mg/kg were again required to signifi-
cantly inhibit tumor growth by 68% and 81%, respectively, as deter-
defined from postmortem tumor weights after 32 days of treatment.
Similar results were obtained for the CAPAN-2 tumors. The C32
melanoma was selected as a representative wild-type ras tumor for in
vivo evaluation. In vitro, R115777 inhibited the proliferation of C32
melanoma with an IC50 of 6 nM (Table 3). Oral administration of
R115777 at doses of 25, 50, and 100 mg/kg, b.i.d. inhibited the growth of
C32 tumors by 48%, 76%, and 90% respectively. In all tumor
studies, the weekly measurements of tumor area were consistent with
the effects of R115777 on postmortem tumor weights (data not
shown). Significant changes in body weight were not observed for
R115777 treatment (data not shown). Analysis of protein prenylation
was attempted in postmortem tumor samples but was not successful
because of the presence of mouse antigens with apparent molecular
masses of 60 kDa and 25 kDa, which crossreacted with our antimouse
IgG secondary antibodies used in Western blot analysis.

**Tumor Histology.** The results from histological analysis of human
tumor xenografts treated with R115777 are summarized in Table 5. In
CAPAN-2 tumors, an antiproliferative effect was observed as statisti-
cally significant reductions at doses of 50 and 100 mg/kg. A modest but significant increase in apoptosis was also observed at the 100 mg/kg dose level. By using combined Factor VIII staining with ISEL, apoptotic cells were found to be relocalized to the endothelial cells of the CAPAN-2 tumor vasculature (Fig. 4). Despite this apparent antiangiogenic event, no significant changes in markers related to angiogenesis (Factor VIII or VEGF) could be detected in CAPAN-2 tumors. In contrast, a marked reduction in the endothelial cell Factor VIII-staining was observed in LoVo human colon tumors, with reductions of 45% and 60% observed at 25 and 50 mg/kg, respectively. LoVo tumors from animals treated with the 100 mg/kg dose of R115777 were too small to prepare for histology. Modest reductions in VEGF staining were also observed, but these did not achieve statistical significance. No significant changes in apoptosis or BrdUrd labeling were observed in LoVo tumors from R115777-treated mice. In the C32 melanoma tumors, yet another profile of

---

### Table 4 Antitumor effects of daily administration of R115777 in nude mouse subcutaneous tumor xenografts

<table>
<thead>
<tr>
<th>Tumor (origin)</th>
<th>ras gene status</th>
<th>Length of treatment (days)</th>
<th>R115777 dose (mg/kg b.i.d.)</th>
<th>Final tumor weight (g)</th>
<th>% inhibition tumor growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>T24 F1 (NIH 3T3)</td>
<td>H-ras (12)</td>
<td>15</td>
<td>Vehicle</td>
<td>1.78 ± 0.41 (a)</td>
<td>52%</td>
</tr>
<tr>
<td></td>
<td>R115777</td>
<td>6.25</td>
<td>0.83 ± 0.15 (a)</td>
<td>84%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12.5</td>
<td>0.29 ± 0.07 (b)</td>
<td>86%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>25</td>
<td>0.25 ± 0.08 (b)</td>
<td>86%</td>
<td></td>
</tr>
<tr>
<td>CAPAN-2 (pancreatic)</td>
<td>K-ras (12)</td>
<td>18</td>
<td>Vehicle</td>
<td>1.05 ± 0.22 (a)</td>
<td>8%</td>
</tr>
<tr>
<td></td>
<td>R115777</td>
<td>25</td>
<td>0.96 ± 0.19 (a)</td>
<td>59%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
<td>0.42 ± 0.09 (b)</td>
<td>68%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>0.24 ± 0.06 (b)</td>
<td>81%</td>
<td></td>
</tr>
<tr>
<td>LoVo (colon)</td>
<td>K-ras (12)</td>
<td>32</td>
<td>Vehicle</td>
<td>0.91 ± 0.12 (a)</td>
<td>8%</td>
</tr>
<tr>
<td></td>
<td>R115777</td>
<td>25</td>
<td>0.82 ± 0.14 (ab)</td>
<td>11%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
<td>0.29 ± 0.07 (bc)</td>
<td>68%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>0.24 ± 0.06 (b)</td>
<td>81%</td>
<td></td>
</tr>
<tr>
<td>C32 (melanoma)</td>
<td>wild type</td>
<td>29</td>
<td>Vehicle</td>
<td>1.88 ± 0.16 (a)</td>
<td>48%</td>
</tr>
<tr>
<td></td>
<td>R115777</td>
<td>25</td>
<td>0.99 ± 0.10 (ab)</td>
<td>48%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
<td>0.45 ± 0.05 (bc)</td>
<td>76%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>0.18 ± 0.02 (c)</td>
<td>90%</td>
<td></td>
</tr>
</tbody>
</table>

---

### Table 5 Quantitative image analysis of histological changes produced by R115777 treatment of human tumor xenografts

<table>
<thead>
<tr>
<th>Tumor (origin)</th>
<th>Treatment</th>
<th>Apoptosis (\text{a}^6)</th>
<th>Proliferation (\text{b}^6)</th>
<th>Angiogenesis (\text{c}^6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lo Vo</td>
<td>Vehicle</td>
<td>1.99 ± 0.70</td>
<td>30.3 ± 1.67</td>
<td>3.26 ± 0.41</td>
</tr>
<tr>
<td>(colon)</td>
<td>R115777</td>
<td>3.10 ± 0.98</td>
<td>25.2 ± 7.68</td>
<td>1.76 ± 0.39</td>
</tr>
<tr>
<td></td>
<td>25 mg/kg</td>
<td>2.90 ± 0.53</td>
<td>22.1 ± 8.10</td>
<td>1.29 ± 0.29</td>
</tr>
<tr>
<td></td>
<td>50 mg/kg</td>
<td>5.54 ± 3.00</td>
<td>27.2 ± 2.37</td>
<td>2.16 ± 0.34</td>
</tr>
<tr>
<td></td>
<td>R115777</td>
<td>9.56 ± 4.26</td>
<td>21.9 ± 1.54</td>
<td>2.94 ± 0.76</td>
</tr>
<tr>
<td></td>
<td>50 mg/kg</td>
<td>10.6 ± 3.00</td>
<td>13.0 ± 0.93</td>
<td>2.43 ± 0.81</td>
</tr>
<tr>
<td></td>
<td>100 mg/kg</td>
<td>4.38 ± 2.90</td>
<td>30.4 ± 16.1</td>
<td>6.8 ± 0.42</td>
</tr>
<tr>
<td>CAPAN-2 (pancreatic)</td>
<td>Vehicle</td>
<td>21.7 ± 19.7</td>
<td>35.1 ± 14.4</td>
<td>6.09 ± 0.50</td>
</tr>
<tr>
<td></td>
<td>R115777</td>
<td>42.0 ± 26.8</td>
<td>35.2 ± 7.16</td>
<td>5.13 ± 0.64</td>
</tr>
<tr>
<td></td>
<td>25 mg/kg</td>
<td>44.2 ± 23.6</td>
<td>37.7 ± 6.53</td>
<td>4.98 ± 0.30</td>
</tr>
<tr>
<td></td>
<td>50 mg/kg</td>
<td>42.0 ± 26.8</td>
<td>35.2 ± 7.16</td>
<td>4.98 ± 0.30</td>
</tr>
<tr>
<td></td>
<td>100 mg/kg</td>
<td>42.0 ± 26.8</td>
<td>35.2 ± 7.16</td>
<td>4.98 ± 0.30</td>
</tr>
</tbody>
</table>

---

\(\text{a}^6\) Data expressed as the percentage of the area per slide with staining signal for VEGF or Factor VIII. Values are means ± SD.

\(\text{b}^6\) Data expressed as the percentage of cells staining positive.

\(\text{c}^6\) Analysis of Lo Vo and CAPAN-2 tumors only.

\(\text{d}^6\) Analysis of C32 melanoma.

\(\text{e}^6\) Statistically significant \(P < 0.05\) form vehicle controls by Wilcoxon Mann-Whitney U Test.
responses to R115777 was observed. R115777 induced a marked, dose-related increase in tumor cell apoptosis. Apoptosis increased from 4.4% in vehicle-treated controls to 22% at 25 mg/kg. At the highest tested doses of 50 and 100 mg/kg, the response appeared to reach a maximum of 41–44% incidence of apoptosis. Staining for the proliferation marker Ki67, VEGF, and Factor VIII were not affected by treatment with R115777 in the C32 melanoma tumors.

**DISCUSSION**

R115777 was a potent inhibitor of isolated human FPT that was competitive for the CAAAX peptide substrate. The molecule was selective for FPT versus PGGT I despite having no obvious structural relationships to the CAAAX recognition motif, which is the basis of selectivity for these two similar enzymes (31, 32). Earlier leads in the chemical series confirmed that the imidazole group is the central pharmacophore prompting the hypothesis that the imidazole interacts with the coordination structure of the zinc catalytic site (33, 34). As with other inhibitors that are competitive for the peptide-binding site, R115777 exhibited a loss of potency with a polylysine containing K-RasB peptide substrate (15).

To a degree, the loss of potency with K-RasB at the level of the enzyme was reflected in studies in intact cells in vitro. Cell lines with N-ras or H-ras mutations responded to lower concentrations of R115777 than did the cell lines bearing K-ras mutations. These findings are consistent with previously published studies, wherein tumors bearing mutant H-ras appear to be far more sensitive to FTIs than tumors bearing K-ras mutations (9, 10, 19, 20, 35, 36). Additionally, the presence of K-ras mutations correlated with resistance to R115777. The latter observation was consistent with resistance to FTIs being conferred by K-RasB protein geranylgeranylation via PGGT I when the farnesyl protein transferase pathway is inhibited (16–18). At the biochemical level, the involvement of K-RasB with the cellular effects of R115777 could not be substantiated. CAPAN-2 human pancreatic tumor cells responded to R115777 in vitro and in vivo. However, unprocessed K-RasB could not be detected at concentrations of R115777, which inhibited the prenylation of lamin B and N-Ras. The data suggested that the mutant K-RasB protein underwent alternative prenylation, but the postulated resistance to the FTI R115777 was absent. The findings support the role for other farnesylated targets mediating the response to the FTI R115777, as has been suggested previously (16–18, 37). Similar results were recently reported for viral-K-ras transgenic mice wherein the FTI l-744,832 produced antitumor effects in the K-RasB-driven tumors without effects on K-RasB prenylation (38). The activity of R115777 in Raf-transformed NIH 3T3 fibroblasts lends additional support to this concept. Despite the conflicting data, gain of geranylgeranylated RhoB remains an attractive hypothesis to explain discordance between Ras processing and the effects of FTIs (21, 22, 33). Although the Ras proteins may not be the primary farnesylated protein required for the activity of FTIs, expression of the different mutant Ras isoforms, in particular K-RasB, does appear to influence the relative sensitivity of tumor cells to this class of compound. Whether this reflects an interaction of farnesylated K-RasB signaling pathway with geranylgeranylated RhoB or the function of centromere-associated proteins is an interesting area for additional research. A point of convergence could be the high-affinity binding sites for prenylated K-RasB found in microtubules (39).

In studies of Ras-processing in the T24 H-ras-transfected NIH3T3 cells, the levels of Ras immunoreactivity consistently decreased. In contrast, the levels of other endogenous farnesylated proteins were noted to increase with the increase derived from the accumulation of unfarnesylated protein. This was also apparent in the immunostaining for K-ras, which remained as a single membrane-associated band in CAPAN-2 cells treated with R115777. Although it has not been systematically explored, the findings suggest the possibility of a feedback to protein expression involving protein trafficking or prenylation. Consistent with the present studies, such a mechanism would not be expected to regulate expression from transfected ras genes, which carry engineered promoters.

In four tumor models, R115777 demonstrated significant antitumor effects when administered b.i.d. by the oral route. Although the sensitivity of the cell lines to the antiproliferative effects of R115777 in vivo mirrored the relative sensitivity of tumors in vitro, histological studies revealed that the responses elicited by R115777 in xenografts involved far more than antiproliferative effects. Computer-assisted quantitative image analysis revealed that R115777 treatment produced predominantly an antiproliferative effect in CAPAN-2 pancreatic tumors, which was accompanied by an induction of apoptosis relegated to the host endothelial cells of the tumor vasculature. A prominent angiogenic effect was observed in LoVo colon tumors, whereas a marked induction of apoptosis was noted in C32 melanoma tumors. The latter effect could not be observed in C32 melanoma cells cultured as monolayers in vitro (data not shown). The effects of R115777 in C32 melanoma are reminiscent of the report that FTI l-739,749 could produce apoptotic effects under conditions of anchorage-independent growth but not in monolayer cultures (40). Either blockade of Ras signaling via the PI3 kinase and Akt pathway or gain of geranylgeranylated RhoB could account for the induction of apoptosis in vivo (23, 41). The emergence of additional antitumor...
activities in test systems more complex than monolayer culture is consistent with FTIs acting to revert to the transformed phenotype, because transformation encompasses survival and proliferation in tumor xenografts.

In conclusion, R115777 is a p.o.-active FTI that demonstrated antitumor effects at nontoxic doses in mice. The variety of histological responses produced by treatment with R115777 suggested that modification of aspects of the malignant phenotype concerned with host-tumor interactions might be an important component of FTI effects.

REFERENCES


Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro

David W. End, Gerda Smets, Alison V. Todd, et al.

Cancer Res 2001;61:131-137.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/1/131

Cited articles
This article cites 39 articles, 26 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/1/131.full#ref-list-1

Citing articles
This article has been cited by 83 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/61/1/131.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/61/1/131.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.